Literature DB >> 31614206

Increased androgen receptor levels and signaling in ovarian cancer cells by VEPH1 associated with suppression of SMAD3 and AKT activation.

Alexandra Kollara1, Premalatha Shathasivam1, Soyeon Park2, Maurice J Ringuette3, Theodore J Brown4.   

Abstract

Studies indicate androgens contribute to initiation or progression of epithelial ovarian cancer through poorly understood mechanisms. We provide evidence that the androgen receptor (AR) interacts in a ligand-independent manner with the putative armadillo repeat domain of ventricular zone expressed PH domain-containing 1 (VEPH1). This interaction was increased by mutation of the two nuclear receptor-interacting LxxLL motifs present within the VEPH1 armadillo repeat domain. Androgen treatment did not result in nuclear co-localization of VEPH1 with AR, suggesting that VEPH1 does not function as a nuclear co-regulatory protein. VEPH1 expression decreased SMAD3 and activated AKT levels in ovarian cancer cell lines and increased AR activity and protein levels, consistent with an impact on receptor stability. Treatment of cells with dihydrotestosterone (DHT) increased AR protein levels measured 24 h after treatment, an effect augmented in VEPH1-transfected cells, and inhibited by knock-down of endogenous VEPH1. SMAD3 overexpression decreased AR protein levels and prevented the VEPH1-dependent increase in AR; however, silencing of SMAD3 paradoxically also decreased AR levels. DHT treatment led to a rapid and sustained decrease in phosphorylated AKT (pAKT) levels that was enhanced by VEPH1 expression. Inhibition of PI3K resulted in increased AR protein levels. These studies indicate that VEPH1 acts to enhance AR activity in ovarian cancer cells by decreasing SMAD3 and pAKT levels, resulting in increased levels of AR protein.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AKT; Androgen receptor; Ovarian cancer; SMAD3; VEPH1

Mesh:

Substances:

Year:  2019        PMID: 31614206     DOI: 10.1016/j.jsbmb.2019.105498

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  4 in total

Review 1.  Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).

Authors:  Hongyi Li; Yu Liu; Yang Wang; Xia Zhao; Xiaorong Qi
Journal:  Oncol Rep       Date:  2021-08-26       Impact factor: 3.906

2.  MicroRNA miR-23b-3p promotes osteosarcoma by targeting ventricular zone expressed PH domain-containing 1 (VEPH1)/phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway.

Authors:  Liang Fan; Xing Cao; Yanrong Lei
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis.

Authors:  Juan Zou; Yukun Li; Nianchun Liao; Jue Liu; Qunfeng Zhang; Min Luo; Jiao Xiao; Yanhua Chen; Mengjie Wang; Kexin Chen; Juan Zeng; Zhongcheng Mo
Journal:  J Ovarian Res       Date:  2022-02-28       Impact factor: 4.234

4.  TGFβ1 orchestrates renal fibrosis following Escherichia coli pyelonephritis.

Authors:  Teri N Hreha; Christina A Collins; Allyssa L Daugherty; Joy Twentyman; Nitin Paluri; David A Hunstad
Journal:  Physiol Rep       Date:  2020-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.